Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13911216 | 1.00 | MAOA (0.64) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL19289840 | 0.90 | HTT (0.64) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL62691 | 0.90 | HTT (0.64) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL62692 | 0.90 | HTT (0.64) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL172566 | 0.90 | MAOA (0.60) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL6923878 | 0.89 | MAOA (0.59) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL6851081 | 0.86 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL10282640 | 0.86 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL6851796 | 0.86 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL18995764 | 0.83 | MAOA (0.59) | MAOAMAOBACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2010059913-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059913-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-27 | — | — | WO | disclosed |
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | disclosed |
| US-5668181-A | INHIBITOR OF MONOAMINE OXIDASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1997-09-16 | — | — | US | disclosed |
| US-5576353-A | ADMINISTERING N-PROPARGYL-1-AMINOINDAN TO A SUBJECT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-11-19 | — | — | US | disclosed |
| US-5457133-A | Treating Parkinson's disease, memory disorders, Alzheimer's disease, depression and hyperactive syndrome | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-10-10 | — | — | US | disclosed |
| US-5453446-A | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-09-26 | — | — | US | disclosed |
| US-5387612-A | Administering title compound or salt; memory disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-02-07 | — | — | US | disclosed |
| EP-0436492-B1 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | TEVA PHARMA (IL) | 1994-06-08 | — | — | EP | disclosed |
| EP-0436492-A2 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | Teva Pharmaceutical Industries Limited (IL) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A4, SLC6A3, SIGMAR1 | MAOA 297/4885MAOB 405/4885ACHE 712/4885 |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | MAOA 47/4885MAOB 37/4885ACHE 89/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | MAOA 285/4885MAOB 463/4885ACHE 812/4885 |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | MAOA 1806/4885MAOB 2001/4885ACHE 2246/4885 |
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | MAOA 1806/4885MAOB 2001/4885ACHE 2246/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | MAOA 64/4885MAOB 57/4885ACHE 117/4885 |
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNQ5 | MAOA 2930/4885MAOB 2879/4885ACHE 1931/4885 |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | MAOA 1806/4885MAOB 2001/4885ACHE 2246/4885 |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SIGMAR1, OPRK1, SLC6A2 | MAOA 171/4885MAOB 283/4885ACHE 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.